BiotechTube

LDV/SOF + RBV

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatitis C Virus

Conditions

Hepatitis C Virus, HIV

Trial Timeline

Feb 1, 2014 → Dec 1, 2015

NCT ID
NCT02073656

About LDV/SOF + RBV

LDV/SOF + RBV is a phase 3 stage product being developed by Gilead Sciences for Hepatitis C Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT02073656. Target conditions include Hepatitis C Virus, HIV.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis C Virus were approved

Approved (20) Terminated (8) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Pegylated Interferon + RibavirinAstellas PharmaApproved
✅Glecaprevir-pibrentasvirAbbVieApproved
✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved
✅PTV/r/OBV/DSVAbbVieApproved
✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved
✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (14)

NCT IDPhaseStatus
NCT02600351Phase 3Terminated
NCT02487030Phase 3Completed
NCT02472886Phase 3Completed
NCT02413593Phase 2Completed
NCT02249182Phase 2Completed
NCT01987453Phase 2Completed
NCT02073656Phase 3Completed
NCT02010255Phase 2Completed
NCT01975675Phase 3Completed
NCT01938430Phase 2Completed
NCT01851330Phase 3Completed
NCT01768286Phase 3Completed
NCT01726517Phase 2Completed
NCT01701401Phase 3Completed

Competing Products

20 competing products in Hepatitis C Virus

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
43
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
40
SOF + COPEChugai PharmaceuticalPre-clinical
26
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
FK788Astellas PharmaPhase 2
35
MK-2248MerckPhase 1
29
Interferon alfacon-1Astellas PharmaPhase 3
40
Pegylated Interferon + RibavirinAstellas PharmaApproved
35
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir + MethadoneShionogiPhase 1
29
Clevudine + AdefovirEisaiPhase 3
40